Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clotrimazole+Lactulose for Candidal Vulvovaginitis
NCT06835361Phase 3Recruiting
- Sponsor
- AVVA Pharmaceuticals Ltd
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of lactulose in vulvovaginal candidiasis (VVC) (3 arms), sponsored by AVVA Pharmaceuticals Ltd. Primary endpoint: Proportion of patients with clinical and microbiological response (recovery) at Day 25. Started Feb 2024; status: recruiting.
02
Drugs
lactulose
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT06835361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835361.